PMV Pharmaceuticals (PMVP) Stock Overview
A precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
PMVP Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
PMV Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.44 |
| 52 Week High | US$1.84 |
| 52 Week Low | US$0.81 |
| Beta | 1.51 |
| 1 Month Change | 20.00% |
| 3 Month Change | 8.27% |
| 1 Year Change | -10.00% |
| 3 Year Change | -87.58% |
| 5 Year Change | -95.90% |
| Change since IPO | -96.16% |
Recent News & Updates
Recent updates
Will PMV Pharmaceuticals (NASDAQ:PMVP) Spend Its Cash Wisely?
Jun 11
Is PMV Pharmaceuticals (NASDAQ:PMVP) In A Good Position To Deliver On Growth Plans?
Aug 04Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Apr 20Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Dec 22We Think PMV Pharmaceuticals (NASDAQ:PMVP) Can Afford To Drive Business Growth
Sep 08Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
May 10PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Good Position To Deliver On Growth Plans
Jan 11Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Sep 22PMV Pharmaceuticals GAAP EPS of -$0.38 beats by $0.04
Aug 09PMV Pharma joins Merck to study lead candidate with Keytruda
Jul 18Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Jun 09Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Feb 23Companies Like PMV Pharmaceuticals (NASDAQ:PMVP) Are In A Position To Invest In Growth
Nov 05Here's Why We're Not Too Worried About PMV Pharmaceuticals' (NASDAQ:PMVP) Cash Burn Situation
Jul 23PMV Pharmaceuticals (NASDAQ:PMVP) Is In A Strong Position To Grow Its Business
Apr 09Do Institutions Own PMV Pharmaceuticals, Inc. (NASDAQ:PMVP) Shares?
Dec 25Shareholder Returns
| PMVP | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 3.6% | 0.9% | -1.2% |
| 1Y | -10.0% | -0.6% | 15.1% |
Return vs Industry: PMVP underperformed the US Biotechs industry which returned -0.6% over the past year.
Return vs Market: PMVP underperformed the US Market which returned 15.1% over the past year.
Price Volatility
| PMVP volatility | |
|---|---|
| PMVP Average Weekly Movement | 11.3% |
| Biotechs Industry Average Movement | 10.6% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 17.6% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: PMVP's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: PMVP's weekly volatility (11%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 47 | David Mack | www.pmvpharma.com |
PMV Pharmaceuticals, Inc., a precision oncology company, engages in the discovery and development of small molecule and tumor-agnostic therapies for p53 mutations in cancer. It’s lead product candidate is rezatapopt, an orally available small molecule that potently and selectively correct p53 misfolding caused by p53 mutation, Y220C, while sparing wild-type p53. The company was formerly known as PJ Pharmaceuticals, Inc. and changed its name to PMV Pharmaceuticals, Inc. in July 2013.
PMV Pharmaceuticals, Inc. Fundamentals Summary
| PMVP fundamental statistics | |
|---|---|
| Market cap | US$76.31m |
| Earnings (TTM) | -US$80.87m |
| Revenue (TTM) | n/a |
Is PMVP overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| PMVP income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$80.87m |
| Earnings | -US$80.87m |
Last Reported Earnings
Jun 30, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.53 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did PMVP perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/10/16 21:46 |
| End of Day Share Price | 2025/10/16 00:00 |
| Earnings | 2025/06/30 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
PMV Pharmaceuticals, Inc. is covered by 10 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Gregory Harrison | BofA Global Research |
| Gum-Ming Lowe | Craig-Hallum Capital Group LLC |
| Joshua Schimmer | Evercore ISI |